Abstract:Abstract Background Among breast cancer (BC) survivors, cardiovascular disease (CVD) is one of the most common comorbidities contributing to mortality. Data on to what extent CVD risk impacts disease progression and second cancers in younger women is limited. We conducted a prospective cohort study to examine whether CVD risk is associated with disease recurrence or new primary cancer among female BC survivors enrolled in a cohort of women with a family history of BC. Methods The study included 301 females with a first primary diagnosis of BC in the Breast and Ovarian Surveillance Service (BOSS) Cohort, after excluding those who had a history of recurrence or second primary cancer prior to enrollment (N=125), a diagnosis of ductal carcinoma in situ (DCIS) (N=66), and with missing CVD risk factors (N=3). A risk score based on 7 CVD risk factors (age 65 or older, diabetes, hypertension, high cholesterol, body mass index (BMI), smoking status, and physical activity) was assessed at baseline and updated 4 and 8 years after enrollment. Each risk factor was given a score (0, 1, or 2) and was summed and categorized into low (score=0 or 1), intermediate (score=2 or 3), and high (score >3) risk. The primary outcome was either BC progression or all second primary cancers. Analyses limited to BC progression and second BC only were also conducted. Outcomes were ascertained through active follow-up and confirmed by pathology records. Kaplan-Meier graphs and two different Cox regression models were used to compare risk groups: model 1 adjusted for participants’ age, race, BMI, time from diagnosis, education, tumor stage, and estrogen receptor (ER) status; model 2 included further adjustment of cancer treatments (chemotherapy, hormone therapy, radiation), statin use, baby aspirin use, and specifically cardiotoxic treatments. For subgroup analyses, a more parsimonious model was used including age, race, BMI, education, cancer treatments, and cardiotoxic treatment. Results Participants’ mean age of BC diagnosis was 47.4 years and the median follow-up time was 11.5 years. The incidence rate of recurrence or any second cancer was 21 cases per 1000 person-years. At baseline, there were 168, 130, and 84 survivors in the low, intermediate, and high CVD risk groups respectively, and their use of statins increased from 12.7%, 34.5% to 52.7%. In the multivariable model, BC survivors with an intermediate CVD risk score had a 2.23 times greater risk of recurrence or second primary cancer as compared to those with a low CVD risk score (95% CI=1.20- 4.17). After further adjusting for cancer and CVD treatment in model 2, the HR was attenuated but still significant to 2.01 (95% CI = 1.20- 4.17. Interestingly, the association was attenuated and non-significant in the high-risk group (model 2: HR=1.37, 95% CI = 0.54- 3.45). The positive association between intermediate CVD risk score and recurrence or second cancer was also observed among subgroups of BC survivors including those who were postmenopausal (HR = 2.23, 95% CI = 1.01-4.93), with ER-positive BC (HR=2.07, 95% CI=1.08-3.99), regional disease (HR = 2.74, 95% CI = 1.06-7.04), diagnosed 5 years or greater (HR = 4.85, 95% CI = 1.14-20.66). There was a significant interaction between intermediated CVD risk and diagnosis time of 5 years (P interaction = 0.033). Restricting the outcome to disease progression and second BC alone led to similar results. The HR comparing the intermediate risk group and low risk group was 2.65 (95% CI = 1.27-5.55) in model 1 and decreased to 2.28 (95% CI = 1.06-4.89) in model 2. Conclusion There was a significant association between CVD risk and subsequent cancer progression in female breast cancer survivors, particularly among long-term BC survivors. The non-significant results among the women with high CVD risk scores may reflect the fact that a greater proportion of these women compared to women in the intermediate group reported taking cardiac treatments that can favorably impact cancer progression. Citation Format: Xinyi Feng, Zhengyi Deng, Michelle McCollough, Betty May, Erica Selznick, Avonne Connor, Deborah K. Armstrong, Kala Visvanathan. The Impact of Cardiovascular Disease Risk on Cancer Progression among Female Breast Cancer Survivors: A Longitudinal Study within The Boss Cohort [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-03-17.

Abstract 3462: Mendelian randomization analysis of 27 cardiometabolic trait related polygenic scores identifies genetic risk for cardiometabolic and cardiovascular events in a large prospective study of breast cancer survivors

Abstract 3007: Monogenic and Polygenic Associations with Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: the St. Jude Lifetime Cohort Study (SJLIFE)

Abstract PD3-02: Polygenic Risk Scores Provide Clinically Meaningful Risk Stratification among Women Carrying Moderate Penetrance Pathogenic Variants in Breast Cancer Predisposition Genes: Results from the CARRIERS Study

Abstract C102: Interactions of a polygenic risk score and modifiable lifestyle factors for breast cancer in the Multiethnic Cohort

Influence of genetic predisposition and lifestyle on modifiable cardiovascular risk factors among survivors of childhood cancer.

Abstract 5241: Association of Polygenic Risk Scores with Breast Cancer Risk among Women with Benign Breast Disease

Abstract P3-19-29: Polygenic Risk Scores Predict Toxicities in Racially Diverse Breast Cancer Patients Following Radiotherapy

Abstract 6382: Risk prediction of dyslipidemia in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort

Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors

Combined Associations of a Polygenic Risk Score and Classical Risk Factors with Breast Cancer Risk

Abstract 818: Association of Polygenic Risk Score and Menopausal Hormone Therapy for Colorectal Cancer Risk

Abstract P2-09-01: Population-based Risk Estimates of Clinical Subtypes of Breast Cancer among Carriers of Germline Pathogenic Variants in Cancer Predisposition Genes

Abstract 3425: Genetic predisposition to obesity and survival in women with breast cancer

Abstract P5-09-02: Breast Cancer Risk Prediction Using a Polygenic Risk Score in Women of African Ancestry: Findings from GWAS in Breast Cancer in the African Diaspora

Risk of Breast Cancer among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.

Abstract GS4-04: Population-based Estimates of contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

Abstract A003: Risks of Ductal Carcinoma in Situ of the Breast Associated with Pathogenic Variants in Cancer Predisposition Genes

Abstract 769: Incorporating a cross-ancestry polygenic risk score into a clinical model improved breast cancer risk prediction in women with pathogenic variants

Abstract 2227: Physical activity at breast cancer diagnosis and incident cardiovascular disease in the Pathways Study

Abstract PR001: Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk

Abstract P3-03-17: The Impact of Cardiovascular Disease Risk on Cancer Progression among Female Breast Cancer Survivors: A Longitudinal Study within The Boss Cohort